文献速递肾小球疾病

IgA肾病合并微血管病变与免疫抑制治疗反应差相关

Microangiopathic lesions associated with poor immunosuppressive therapy response in IgA nephropathy.
PubMed 文献 · Nephrol Dial Transplant · 2026-10-15

这项前瞻性队列研究纳入620例经活检证实、在优化支持治疗至少3个月后仍持续蛋白尿≥1 g/d并接受免疫抑制治疗超过6个月的IgA肾病患者,评估肾小动脉微血管病变与治疗反应的关系。结果显示,24.8%的患者存在微血管病变,其免疫抑制治疗无反应率显著更高(61.0% vs. 26.2%),多变量分析显示微血管病变独立关联无反应风险增加(OR 4.04,95%CI 2.61-6.25)。

要点

  • IgA肾病患者中肾小动脉微血管病变并不少见(24.8%)。
  • 合并微血管病变者免疫抑制治疗无反应率显著更高(61.0% vs. 26.2%)。
  • 微血管病变独立关联无反应风险增加(OR 4.04,95%CI 2.61-6.25)。

核心结论

  • 肾小动脉微血管病变在IgA肾病中相对常见,且与更差的临床结局和免疫抑制治疗反应不佳相关。

研究设计与样本

  • 前瞻性队列研究,纳入620例经活检证实的原发性IgA肾病患者。
  • 纳入标准为优化RASi支持治疗至少3个月后仍持续蛋白尿≥1 g/d,并接受免疫抑制治疗超过6个月。
  • 肾小动脉微血管病变由两位病理学家独立审阅。

主要发现

  • 154例(24.8%)存在肾小动脉微血管病变。
  • 合并微血管病变者血压更高、蛋白尿更重、eGFR更低。
  • 微血管病变组免疫抑制治疗无反应率为61.0%,无微血管病变组为26.2%。
  • 多变量logistic回归显示微血管病变独立关联无反应风险增加(OR 4.04,95%CI 2.61-6.25)。
  • 倾向性评分匹配后及所有预设亚组中关联一致。

关键数值与推荐

  • 主要结局治疗反应定义为蛋白尿较基线下降≥50%且<1 g/d,同时eGFR下降<25%。

临床怎么用

  • 对IgA肾病患者应关注肾小动脉微血管病变的病理评估。
  • 合并微血管病变者可能对常规免疫抑制治疗反应较差,需考虑替代或靶向治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND HYPOTHESIS: Renal arteriolar microangiopathic lesions are frequently observed in immunoglobulin A nephropathy (IgAN). However, their impact on the response to immunosuppressive therapy remains unclear. This study aimed to evaluate the association between these lesions and treatment response in patients with IgAN. METHODS: In this prospective cohort study, we included 620 patients with biopsy-proven primary IgAN who had persistent proteinuria ≥1 g/d despite at least 3 months of optimized supportive care with renin-angiotensin system inhibitors (RASi) and subsequently received immunosuppressive therapy for >6 months. Renal arteriolar microangiopathic lesions were independently reviewed by two pathologists. The primary outcome was treatment response, defined as a ≥50% reduction in proteinuria from baseline to <1 g/day, combined with an estimated glomerular filtration rate (eGFR) decline of <25%. Logistic regression, propensity score matching (PSM), and subgroup analyses were used to assess the association between microangiopathic lesions and treatment response. RESULTS: Among the 620 enrolled patients, 154 (24.8%) had renal arteriolar microangiopathic lesions. Compared to patients without microangiopathic lesions, those with microangiopathic lesions had higher blood pressure, more severe proteinuria, and lower eGFR. The non-response rate to immunosuppressive therapy was significantly higher in patients with microangiopathic lesions than in those without (61.0% vs. 26.2%). Multivariable logistic regression indicated that the presence of microangiopathic lesions was independently associated with an increased risk of non-response (odds ratio 4.04, 95% confidence interval 2.61-6.25). This association remained consistent after PSM and across all prespecified subgroups. CONCLUSION: Renal arteriolar microangiopathic lesions are relatively common in IgAN and are associated with worse clinical outcomes and poorer response to immunosuppressive therapy. These findings suggest that conventional immunosuppression may be less effective for this high-risk subgroup, necessitating further research into targeted therapeutic strategies.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Zhong Z, Zhao H, Jia N, et al. Microangiopathic lesions associated with poor immunosuppressive therapy response in IgA nephropathy. Nephrol Dial Transplant. 2026. PMID: 42878692. doi:10.1093/ndt/gfag237

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。